Erythromycin: an alternative for the management of oral mucositis?
Med. oral patol. oral cir. bucal (Internet)
; 27(5): e452-e459, September 01, 2022. tab, ilus
Artigo
em Inglês
| IBECS
| ID: ibc-209812
Biblioteca responsável:
ES1.1
Localização: ES15.1 - BNCS
ABSTRACT
Background:
Oral mucositis (OM) is an important acute adverse effect of anticancer therapy. This condition presents high morbidity and may lead to the suspension of anticancer therapy.Material andMethods:
We reviewed the literature on the pathobiology of OM and the properties of erythromycin(EM), to consider the possibility of its use for the prevention and treatment of OM. We searched the PubMed,Scopus and Web of Science databases and selected complete articles published in English or Spanish that met theinclusion criteria. The search terms erythromycin, inflammation, immunomodulation and oral mucositiswere used.Results:
The control of free radicals, transcription factors and pro-inflammatory cytokines has been consideredas the key to the management of OM. EM has the ability to modulate oxidative stress, acts on the transcriptionalsystem and inhibits the production of several cytokines that have been directly implicated in OM pathobiology.Conclusions:
The present review suggests that EM could be effective in the treatment of OM. Experimental studies investigating the use of EM in OM should be encouraged. (AU)
Texto completo:
Disponível
Coleções:
Bases de dados nacionais
/
Espanha
Base de dados:
IBECS
Assunto principal:
Estomatite
/
Eritromicina
/
Citocinas
/
Estresse Oxidativo
/
Mucosite
/
Imunomodulação
/
Inflamação
Limite:
Humanos
Idioma:
Inglês
Revista:
Med. oral patol. oral cir. bucal (Internet)
Ano de publicação:
2022
Tipo de documento:
Artigo
Instituição/País de afiliação:
Pontifical Catholic University of Rio Grande do Sul-PUCRS/Brazil